AU2002217431A1 - Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis - Google Patents

Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis

Info

Publication number
AU2002217431A1
AU2002217431A1 AU2002217431A AU1743102A AU2002217431A1 AU 2002217431 A1 AU2002217431 A1 AU 2002217431A1 AU 2002217431 A AU2002217431 A AU 2002217431A AU 1743102 A AU1743102 A AU 1743102A AU 2002217431 A1 AU2002217431 A1 AU 2002217431A1
Authority
AU
Australia
Prior art keywords
isovaleryl
carnitine
osteoporosis
cure
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217431A
Other languages
English (en)
Inventor
Aleardo Koverech
Alberta Zallone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2002217431A1 publication Critical patent/AU2002217431A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2002217431A 2000-12-21 2001-12-04 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis Abandoned AU2002217431A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM200A000688 2000-12-21
IT2000RM000688A IT1317079B1 (it) 2000-12-21 2000-12-21 Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
PCT/IT2001/000614 WO2002049639A1 (en) 2000-12-21 2001-12-04 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis

Publications (1)

Publication Number Publication Date
AU2002217431A1 true AU2002217431A1 (en) 2002-07-01

Family

ID=11455074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217431A Abandoned AU2002217431A1 (en) 2000-12-21 2001-12-04 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis

Country Status (15)

Country Link
US (2) US6906102B2 (sk)
EP (1) EP1351676B1 (sk)
AT (1) ATE301998T1 (sk)
AU (1) AU2002217431A1 (sk)
CA (1) CA2434962C (sk)
CZ (1) CZ304356B6 (sk)
DE (1) DE60112802T2 (sk)
DK (1) DK1351676T3 (sk)
ES (1) ES2247005T3 (sk)
HU (1) HU227342B1 (sk)
IT (1) IT1317079B1 (sk)
MX (1) MXPA03006332A (sk)
PL (1) PL207879B1 (sk)
SK (1) SK287306B6 (sk)
WO (1) WO2002049639A1 (sk)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291141B1 (it) * 1997-04-16 1998-12-29 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti
IT1299191B1 (it) 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa

Also Published As

Publication number Publication date
DE60112802D1 (de) 2005-09-22
HUP0400735A3 (en) 2009-01-28
US20050143458A1 (en) 2005-06-30
CZ20031890A3 (cs) 2004-04-14
US7084174B2 (en) 2006-08-01
ES2247005T3 (es) 2006-03-01
HUP0400735A2 (hu) 2004-07-28
ITRM20000688A1 (it) 2002-06-21
WO2002049639A1 (en) 2002-06-27
CA2434962C (en) 2010-02-09
SK287306B6 (sk) 2010-06-07
DK1351676T3 (da) 2005-12-19
PL367293A1 (en) 2005-02-21
ATE301998T1 (de) 2005-09-15
EP1351676B1 (en) 2005-08-17
IT1317079B1 (it) 2003-05-26
SK8912003A3 (en) 2003-11-04
PL207879B1 (pl) 2011-02-28
EP1351676A1 (en) 2003-10-15
MXPA03006332A (es) 2004-04-21
ITRM20000688A0 (it) 2000-12-21
CA2434962A1 (en) 2002-06-27
CZ304356B6 (cs) 2014-03-26
US6906102B2 (en) 2005-06-14
DE60112802T2 (de) 2006-03-16
US20040077718A1 (en) 2004-04-22
HU227342B1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
AU7031500A (en) Therapeutic quinazoline compounds
GEP20043354B (en) Therapeutic Formulation for Administering Tolterodine with Controlled Release
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
WO1994027589A3 (en) Antidepressant dosage form
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL122546A0 (en) Use of a combination of ritonavir and a drug metabolized by cytochrome p450 monooxygenase in the preparation of medicaments and pharmaceutical compositions containing the combination
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
WO1997005862A3 (en) Use of basic amino acids and derivatives for lowering ceramide levels
AU2001249684A1 (en) Nasal administration of agents for the treatment of gastroparesis
GB9907571D0 (en) Compounds
WO2003018535A3 (en) Novel aminobenzoephenones
AU2002217431A1 (en) Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis
AU2003249472A1 (en) Use of angelicin and of its structural analogues for the treatment of thalassemia
WO2004004697A3 (en) A novel use of rapamycin and structural analogues thereof
AU2002252610A1 (en) Ultrasonic profiling of medicament administration into tissue
ZA95908B (en) A synergistic formulation for treatment of rheumatic diseases
WO2002030955A3 (en) Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use
AU2003244067A1 (en) A formulation of traditional chinese medicine for preventing and treating osteoporosis
CA2403674A1 (en) The use of t3 for treating congestive heart failure
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
AU6702596A (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
AU2002213232A1 (en) Treatment of demyelinating diseases by administering gpe
AU2002238405A1 (en) Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases